Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Endocrinology and Metabolism ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A prospective study of postmenopausal estrogen therapy and coronary heart disease.N Engl J Med. 1985; 313: 1044-1049
- Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.JAMA. 1998; 280: 605-613
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.JAMA. 2002; 291: 1701-1712
- Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial.BMJ. 2012; 345: e6409
- Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women.Ann Intern Med. 2014; 161: 249-260
- Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis.Menopause. 2015; 22: 391-401
Article info
Publication history
Published online: June 22, 2015
Footnotes
Disclosures: Dr Bender is a consultant for Merck; Dr Nkonda-Price: None.
The authors have nothing to disclose.
Identification
Copyright
© 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
